The therapeutic inhibition of TGFβ signaling is currently under clinical investigation for multiple oncological indications, including NSCLC, following several different approaches [40,49]: TGFβ antibody treatment (Fresolimumab); inhibition of Smad phosphorylation with kinase inhibitors (Galunisertib); RNA silencing approaches (Trabedersen) and vaccination techniques (Lucanix, Vigil). Here, TGFB1 is linked to non-small cell lung carcinoma.